Craig Hallum initiated coverage on Cardiff Oncology with a new price target - Quantisnow

First patient dosed in ONSEMBLE Phase 2 trial of Onvansertib for KRAS/NRAS-mutated mCRC. SAB full membership introduced. Fairooz Kabbinavar appointed as CMO. $97 million in cash, equivalents, and short-term investments as of March 31, 2023, with runway into 2025.